Structural and Functional Integration of the PLCγ Interaction Domains Critical for Regulatory Mechanisms and Signaling Deregulation  by Bunney, Tom D. et al.
Structure
ArticleStructural and Functional Integration
of the PLCg Interaction Domains Critical
forRegulatoryMechanismsandSignalingDeregulation
Tom D. Bunney,1 Diego Esposito,2 Corine Mas-Droux,1 Ekatarina Lamber,3 Rhona W. Baxendale,1 Marta Martins,1
Ambrose Cole,4 Dmitri Svergun,5 Paul C. Driscoll,2 and Matilda Katan1,*
1Institute of Structural and Molecular Biology, Division of Biosciences, University College London, Gower Street, London WC1E 6BT, UK
2Division of Molecular Structure, MRC-National Institute for Medical Research, Mill Hill, London NW7 1AA, UK
3Research Institute of Molecular Pathology, Dr. Bohr-Gasse 7, 1030 Vienna, Austria
4ISMB, Birkbeck College, London WC1 7HX, UK
5European Molecular Biology Laboratory, Hamburg Outstation c/o DESY, Notkestrasse 85, 22603 Hamburg, Germany
*Correspondence: m.katan@ucl.ac.uk
http://dx.doi.org/10.1016/j.str.2012.09.005
Open access under CC BY license.SUMMARY
Multidomain proteins incorporating interaction
domains are central to regulation of cellular pro-
cesses. The elucidation of structural organization
andmechanistic insights into many of these proteins,
however, remain challenging due to their inherent
flexibility. Here, we describe the organization and
function of four interaction domains in PLCg1 using
a combination of structural biology and biochemical
approaches. Intramolecular interactions within the
regulatory region center on the cSH2 domain, the
only domain that also interacts with the PLC-core. In
the context of fibroblast growth-factor receptor sig-
naling, the coordinated involvement of nSH2 and
cSH2 domains mediates efficient phosphorylation of
PLCg1 resulting in the interruptionof anautoinhibitory
interface by direct competition and, independently,
dissociation of PLCg1 from the receptor. Further
structural insights into the autoinhibitory surfaces
provide a framework to interpret gain-of-function
mutations in PLCg isoforms linked to immune disor-
ders and illustrate a distinctmechanism for regulation
of PLC activity by common interaction domains.
INTRODUCTION
Selective intermolecular interactions are crucial to cellular regu-
latory processes and are usually mediated by modular protein
domains. There are around 100 families of interaction domains
in humans, each of which can be found in many copies; these
therefore represent a prevalent feature of the human proteome
(Liu et al., 2006; Scott and Pawson, 2009). Modules such as
the Src homology 2 (SH2), Src homology 3 (SH3), and pleckstrin
homology (PH) domains represent prototypes, respectively, for
their involvement in recognition of specific motifs generated by
posttranslational modifications, recognition of polypeptide
motifs characterized by specific composition and binding to
phospholipid ligands.2062 Structure 20, 2062–2075, December 5, 2012 ª2012 Elsevier LtdTaking SH2 domains as an example, there is a notable
difference in the number of structures reported for the isolated
domains, free or bound to phosphotyrosine (pY)-containing
polypeptide ligands, compared to larger structures of proteins
encompassing or interacting with this domain (Liu et al., 2006).
The importance of this more comprehensive information has
been recently illustrated by the finding that the selectivity of
fibroblast growth factor receptor (FGFR) is controlled by a
secondary SH2 domain binding site, challenging the view that
short, linear polypeptides can recapitulate the SH2 domain
recognition of their native targets (Bae et al., 2009). Furthermore,
several structures of nonreceptor tyrosine kinases including Src,
Zap70, Fes (Filippakopoulos et al., 2009), tyrosine phosphatase
SHP-2 (Hof et al., 1998), and more recently of lipid kinase PI3Kb
(Zhang et al., 2011) clearly show that SH2 domains are not
mere passive docking devices. Once covalently linked to other
domains, SH2 domains can acquire specific intramolecular inter-
actions that provide a means for regulation of the entire protein.
Therefore, generation of comprehensive data regarding the
organization and functions of themultidomain proteins is needed
to further the understanding of the role of the diverse set of
protein interaction domains and their specific modular function
when integrated within larger polypeptides.
Most multidomain proteins have at least some degree of
segmental mobility facilitated by the flexibility of the interdomain
linkers (Bernado´ and Svergun, 2012). This allows conformational
changes that in some instances can be brought about by
concerted domain movement from one distinct arrangement to
another. In other cases, highly flexible linkers could result in a
great number of conformations being sampled by a protein.
Methodology to obtain structural insights into the organization
of flexible proteins, however, still represents a challenge. Struc-
ture determination by X-ray crystallography is often either com-
plex or not possible; however, lower resolution methods that
analyze proteins in solution such as nuclear magnetic resonance
spectroscopy (NMR) or small angle X-ray scattering (SAXS)
provide an alternative route to understanding structural organi-
zation of these proteins (Bernado´ and Svergun, 2012).
Among families of proteins involved in signal transduction,
phospholipase C (PLC) enzymes that generate second messen-
gers from phosphatidylinositol 4,5-bisphosphate (PIP2) incorpo-
rate a number of different protein modules. PLCg enzymesAll rights reserved
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Figure 1. PLCg1 Requirements for Activa-
tion by FGFR1 in PAE Cells
(A) Schematic representation of the domains of
PLCg1 highlighting the g1SA; the numbering of the
amino acid residues is for human PLCg1.
(B) Dose-response curve of FGFb activation on
PLCg1. PLC activity measurements for full-length
PLCg1wt were performed in PAE cells either un-
transfected or transfected with pTriEx4-PLCg1wt
and stimulated with increasing concentrations of
FGFb/Heparin. Western blottingwas used to show
expression of endogenous and transfected PLCg1
as well as Y783 phosphorylation at different
concentration of FGFb used for dose-response
curve; lanes 1–6 correspond to 0, 3.15, 6.25,
12.50, 25.00, and 50.00 ng/ml of FGFb (inset).
(C) The effects of point mutations on PLCg1
activity were measured in PAE cells transfected
with pTriEx4-PLCg1wt and constructs containing
point mutations inactivating for nSH2 (R586L),
cSH2 (R694L, R696L), or phosphorylation (Y783F)
as well as multi Y to F (Y186, 472, 481, 771, 775,
959, 977, and 1254) replacements, with and
without FGFb/Heparin stimulation. Western blot-
ting was used to show either equal expression
(lanes 1–5 correspond to control, Wt, Y783F,
R586L and R694L, R696L; left inset) or phos-
phorylation on Y783 (lanes 1–8 correspond to
eight columns in the histogram; right inset). SD is
represented by error bars.
See also Figure S1.
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Interaction Domains in PLCg Regulation Mechanisms(PLCg1 and PLCg2), for example, contain eight domains, four of
which are unique to this PLC family (Bunney and Katan, 2011;
Suh et al., 2008). The PLCg ‘specific array’ of domains (gSA),
comprising a ‘‘split’’ PH (spPH) domain flanking two tandem
SH2 domains and an SH3 domain, is inserted between the
two halves (X and Y) of the TIM-barrel catalytic domain
(Bunney and Katan, 2011). As with other PLC families, PLCg
enzymes are key components of core processes in signaling
networks regulated by diverse extracellular signals. Further-
more, both PLCg enzymes have also been implicated in aberrant
cellular responses linked to disease development (Bunney and
Katan, 2010; Everett et al., 2009); one recent example is a link
between dominantly inherited complex immune disorders and
gain-of-function mutations in PLCg2 (Ombrello et al., 2012).
However, due to lack of more comprehensive structural
information, the molecular aspects of the regulatory mecha-
nisms and their subversion by gain-of-function mutations are
not well understood.
For the studies reported here, we focused on PLCg1 in the
context of growth-factor stimulation. Findings describing the
structural organization and integration of individual domains
reveal aspects of regulatory mechanisms and critical molecular
insights relevant for the function of both PLCg enzymes and,
more generally, for other multidomain proteins.
RESULTS
Activation of PLCg1 by FGFR
Themost comprehensive studies of PLCg enzymes have been in
cellular systems that respond to growth factor stimulation and inStructure 20, 2062–20cells from the immune system reacting to stimulation by antigens
(Suh et al., 2008). Most insights into the requirements for
specific domains or phosphorylation sites were obtained by
introducing PLCg variants into different cell types and inducing
subsequent stimulation; this type of experiment has suggested
some general similarity but also some cell system-specific
features. Activation of PLCg1 via FGFR has been clearly
demonstrated and the requirement of a single phosphorylated
tyrosine (pY766 for FGFR1) in the unstructured receptor
C-terminal tail has been shown to be necessary and sufficient
for the recruitment of PLCg isoforms (Bae et al., 2009). However,
the requirements for the functionality of specific regulatory
modules (Figure 1A) and identification of critical phosphorylation
sites for the activation of PLCg1 have not been assessed in
this system. To address this, we used a previously described
porcine aortic endothelial (PAE) cell line expressing transgenic
FGFR1 (Cross et al., 2000); we found that this cell line
provides an excellent model where FGFR1 levels allow a
physiological activation of transfected PLCg1 by fibroblast
growth factor, basic (FGFb). We measured basal as well as
FGFb-stimulated PLC activity of wild-type PLCg1 and variants
with specific point mutations (Figure 1). We first established
activation of PLCg1 by FGFb in a dose-dependent manner
and that this activation is consistent with increased phosphory-
lation of residue Y783 (Figure 1B). We then demonstrated
that the functionality of both SH2 domains and phosphorylation
of Y783, a residue previously implicated in activation of this
enzyme by platelet-derived growth factor and epidermal growth
factor (Suh et al., 2008), are also critical for full activation via
FGFR1 (Figure 1C). Furthermore, based on an analysis of75, December 5, 2012 ª2012 Elsevier Ltd All rights reserved 2063
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Figure 2. Relative Mobility and Interactions between Domains within gSA
(A) Schematic representation of the domains in the gSA construct.
(B) The two-dimensional 1H-15N HSQC spectra of the 15N-labeled gSA construct (left panel) and the overlaid spectra of the spPH, nSH2, and SH3 domains
(right panel).
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Table 1. X-Ray Crystal Structures Data Collection and
Refinement Statistics: Molecular Replacement
nSH2-cSH2wt nSH2-cSH2Y771F,’Y775F,’pY783
Data Collection
Space group P21221 P1
Cell dimensions
a, b, c (A˚) 53.7 59.6 76.9 54.9 59.2 79.2
a, b, g () 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Resolution (A˚) 44.06–2.4
(2.68–2.4)
47.42–2.8
(2.95–2.8)
Rsym or Rmerge 0.045 (0.974) 0.099 (0.762)
RmeasP1/P21221 0.048/0.051 0.139/0.161
//s/ 17.4 (1.7) 6.2 (1.1)
Completeness (%) 96.2 (96.2) 92.1 (96.4)
Redundancy 4.5 (4.5) 2.0 (2.0)
Refinement
Resolution (A˚) 2.4 2.8
Total No. 9,496 22,717
reflections
Rwork/Rfree 0.219/0.295 0.184/0.249
No. atoms
Protein 1,802 7,492
Ligand/ion 0 0
Water 32 249
B-factors
Protein 79.829 54.774
Ligand/ion – –
Water 67.11 34.125
Rmsds
Bond lengths (A˚) 0.010 0.010
Bond angles () 1.11 1.33
One crystal was used for each data collection. Values in parentheses
are for highest-resolution shell. Rfree values are 5% of total number of
reflections.
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Interaction Domains in PLCg Regulation Mechanismsin vitro tyrosine-phosphorylation sites detected by mass
spectrometry, we found that mutations of individual, additional
phosphorylation sites (Figure S1 available online) or a combi-
nation of these sites (Figure 1C) had little effect on activation
of PLCg1. Therefore, it is unlikely that phosphorylation of
any tyrosine residue other than Y783 critically contributes to
activation.
The data obtained using this specific cellular signaling envi-
ronment (Figure 1) provide physiologically relevant information
for further structural and mechanistic studies aimed to define(C) An overlaid surface and cartoon representation of the X-ray crystal structure o
data recorded or predicted for the nSH2-cSH2wt tandem and individual domains
(D) Overlay of regions of the 1H-15N HSQC spectra of the spPH domain (purple) an
the spPH-cSH2 tandem (orange; left panels). Amino acid residues with affected
interface residues on the spPH (blue) and cSH2 (green; right panel). Y509, mutat
(E) Overlay of regions of the 1H-15N HSQC spectra of the gSA (gray) with the S
residues with affected chemical shifts are marked on the spectra. Surface repres
cSH2-SH3 linker (right panel) and the SH3 domain bound to a polyproline peptid
See also Figure S2.
Structure 20, 2062–20the roles for the implicated regulatory, modular structures and
critical tyrosine phosphorylation.
Architecture of the gSA
The key regulatory elements for activation (Figure 1) and previ-
ously described regions of autoinhibition in PLCg enzymes (Ever-
ett et al., 2011; Gresset et al., 2010) are present within the gSA.
Therefore, further mechanistic insights are crucially dependent
on understanding themolecular properties of this region. Despite
the information available for the isolated globular domains from
the gSA (including Protein Data Bank [PDB] codes 2FJL, 3GQI,
and 2HSP), the structure of this entire regulatory region has not
been reported and gSA does not appear to be amenable to crys-
tallographic approaches; this could be due to relative mobility of
itsmodular components. To address this, we have used a combi-
nation of methods including NMR, SAXS and crystallography of
regionswithin the gSA to obtain insights into the overall structural
and dynamic characteristics of this regulatory region.
The gSA construct is characterized by the pseudo-cyclic
nature of the protein in which the N- and C-termini of the poly-
peptide are brought together in a noncovalent fashion in the
context of the stable globular spPH domain (Figure 2A). In the
first set of experiments shown in Figures 2 and S2, this protein
and a number of derived constructs (including single, isolated
domains and their combinations) were extensively characterized
by 2D 15N,1H-HQSC NMR spectroscopy. In addition, we solved
the structure of the tandem nSH2-cSH2 pair by X-ray crystallog-
raphy (Figure 2C; Table 1).
Comparison of the NMR spectra of the gSA with those of the
overlaid individual component domains (Figures 2B and S2A)
reveals that the majority of the well-dispersed cross peaks are
derived from the spPH, nSH2 and SH3 domains. Allowing for
some chemical shift perturbations, it appears that the cross
peak pattern for each of these three domains closely overlaps
a subset of peaks displayed in the context of the larger protein
(Figure 2B), an outcome that suggests that the overall structure
of these domains is retained in the SA construct. In contrast to
these three domains, the majority of the resolved cross peaks
identified in the spectrum of the isolated cSH2 domain are either
broad or absent from the gSA spectrum unless the gSA is bound
to the SH2 domain ligand phosphopeptides (Figure S2B). There
could be several reasons for these observations, however, the
most likely explanation is that the line broadening is due to inter-
mediate timescale chemical exchange resulting from transient
contacts with other parts of the gSA protein that are reduced
after phosphopeptide binding. Overall, the comparative analysis
of the NMR spectra of isolated domains and that of gSA yielded
backbone resonance assignments for over 175 residues of the
larger protein (Figure S2C).f the nSH2-cSH2wt apo-protein (left panel). A histogram showing 15N relaxation
(right panel).
d the cSH2 domain (green) with either the gSA (gray), the gSADSH3 (purple), or
chemical shifts are marked on the spectra. Surface representation showing
ions of which have previously been reported, is underlined.
H3 (red), cSH2-SH3 tandem (yellow) and the linker-SH3 (orange). Amino acid
entation of the SH3 showing amino acid residues (red) at the interface with the
e (PDB code 1YWO; right panel inset).
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Figure 3. Low-Resolution ‘‘Envelope’’ and
Overall Architecture of gSA
(A) SAXS-derived envelope of the gSA. Two views
of the averaged envelope (surface representation)
are displayed and in the inset, the MONSA derived
domain arrangement is superimposed. The enve-
lope has a volume corresponding to the average
volume of individual models.
(B) Representation of an internal domain structure
of the individual gSA domains, using a rigid
body docking protocol implemented in the
program XPLOR-NIH. Individual, structurally
defined domains are shown as ribbon represen-
tations within translucent surfaces correspond-
ing to their surface topology. The scale of this
model is the same as SAXS-derived envelope
shown in A.
See also Figures S3 and S4 and Table S1.
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Interaction Domains in PLCg Regulation MechanismsBased on the determination of the crystal structure of the
PLCg1 tandem nSH2-cSH2 domains in nonliganded form (Fig-
ure 2C, left), suggesting that these SH2 domains might possess
limited intramolecular flexibility with respect to each other, we
directly tested this hypothesis. We recorded 15N relaxation
data on the tandem and isolated SH2 domains. The error-
weighted mean 15N R2/R1 ratio (24.0 ± 0.7) obtained for 68
resolved cross peaks, is substantially larger than would be ex-
pected for the isolated domains. The corresponding derived
isotropic rotational correlation time (15.5 ± 0.6 ns; TENSOR2)
is closer to that predicted from the X-ray crystal structure using
hydrodynamic modeling (18.6 ns; HYDRONMR) applied to resi-
dues 549–772 of the tandem than to the prediction for the
isolated domains (7.4 and 8 ns) (Figure 2C, right). This suggests
that the tandem construct tumbles as a more-or-less rigid entity
in solution.
The comparative analysis of the NMR spectra combined with
backbone NMR assignments, also revealed surfaces of indi-
vidual domains likely to be involved in weak interactions within
the gSA. Comparison of the gSA with deletion variants lacking
either the SH3 domain (gSADSH3) or both the SH3 and nSH2
domains (spPH-cSH2) revealed that chemical shifts of subsets
of spPH and cSH2 cross peaks are perturbed relative to the
isolated domains (Figure 2D). These chemical shift perturbations
correspond to nonrandom clusters of residues biased to one
surface of spPH and cSH2 suggesting transient interactions
between these domains both in the deletion mutants and the
gSA construct. As discussed below, it has been suggested
that the spPH/cSH2 interface is important in maintaining enzy-
matic autoinhibition (DeBell et al., 2007). Furthermore, the
intramolecular surface on spPH is on the opposite side to the
interaction site with Rac—determined for the spPH domain
from PLCg2 (Bunney et al., 2009)—while the interaction surface
on cSH2 does not overlap with the phosphopeptide-binding
pocket. Similarly, analysis of another set of constructs (Figure 2E)
suggests that a cluster of residues on the surface of the SH3
domain transiently interacts with the cSH2-SH3 linker. In this
case, however, the implicated surface overlaps in part with the
region involved in binding of polyproline peptides (Figure 2E,2066 Structure 20, 2062–2075, December 5, 2012 ª2012 Elsevier Ltdinset) suggesting that proline residues from the linker might be
involved in the interaction.
In order to model gSA, SAXS data were recorded for the gSA
polypeptide and a variety of related constructs (Table S1). The
radius of gyration Rg and the maximum dimension Dmax
values (3.2 and 10.5 nm, respectively) obtained for gSA suggest
an elongated overall shape. This finding is supported by the low-
resolution shapes computed ab initio from the SAXS data with
DAMMIN (Volkov and Svergun, 2003); the surface of the average
of several DAMMIN gSA reconstructions is shown in Figure 3A.
Given the potential for dynamic disorder suggested by NMR
(Figure 2), to assess the flexibility of the protein from the SAXS
data we applied the ensemble optimization method (EOM;
Bernado´ et al., 2007; Figure S4). The EOM analysis was per-
formed under a series of different assumptions concerning the
degree of interdomain linker dynamics. The quantitative outputs
of this procedure were sensitive to the assignment of ordered
and disordered regions of the linker segments. Importantly, the
reconstructed distributions of the overall parameters (Rg and
Dmax) are compatible with the incorporation of the contact
between cSH2 and spPH domains (supported by both NMR
data and SAXS data for the cSH2-spPH construct; Figure 2D;
Table S1). Moreover, the Rg/Dmax distributions of the selected
ensembles were narrower compared to the initial random pools
(which assumed complete linker disorder) suggesting limited
linker flexibility with the globular domains each sampling a rela-
tively restricted volume (Figure S4B).
To further probe the domain organization of gSAwe performed
analysis of SAXS data obtained for gSA itself, gSADSH3 and
constructs containing domain pairs nSH2-cSH2, cSH2-SH3
and spPH-cSH2. We applied MONSA (Svergun, 1999), a
program that simultaneously fits multiple scattering patterns to
produce self-consistent ab initio low resolution models. We
generated a model for gSA (c2 = 1.19) shown in Figure S3A,
where different colors indicate the individual domains. Further
validation is provided by MONSA pairwise analysis of the scat-
tering data of gSA with gSADSH3, gSA expressed with an
N-terminal SUMOtag (SUMO-gSA), and a stable complex
formed between gSA and the kinase domain of FGFR1All rights reserved
Structure
Interaction Domains in PLCg Regulation Mechanisms(FGFR1/gSA) where the interaction is centered on the nSH2
domain (Figure S3B). Together, the derivedmodel and additional
data (Figure S3) suggest a spatial arrangement for the compo-
nent domains of gSA where the central lobe of the molecular
volume is occupied by the spPH and cSH2 domains, sand-
wiched between the nSH2 and SH3 domains (Figure 3A, inset).
Given the limited flexibility of gSA suggested by the EOM anal-
ysis, we further generated a model of its domain structure in
terms of the orientation and position of the different domains.
We employed a rigid body docking protocol implemented in
the program XPLOR-NIH that can incorporate a variety of exper-
imental data types, including SAXS data and other structural
information (Figure 3B). For this procedure we treated the
spPH, SH3 and nSH2-cSH2 tandem as rigid entities, assumed
that the intervening segments were unrestrained and introduced
ambiguous distance restraints between the spPH and cSH2
domains based on our NMR data. We consistently obtained
models that give a good fit to the SAXS data for gSA (CRYSOL
c2 0.85, XPLOR-NIH RMSD 0.93) with domain arrangement
consistent with the MONSA analysis (Figures 3A and 3B).
Taken together with the relatively narrow line widths in the
NMR spectra for the 52 kDa gSA construct (Figures 2 and S2)
the model depicted in Figure 3 most likely reflects the dynami-
cally averaged conformation for the protein, and the globular
SH3, spPH and tandem nSH2-cSH2 units can explore, in
a limited way, different relative orientations with little variation
of the overall molecular dimensions.
gSA and Regulation of PLCg1
Previous studies of PLCg1 pointed to marked differences in the
binding properties of the two SH2 domains (Bae et al., 2009;
Gresset et al., 2010). Using an NMR approach, we found that
the nSH2 domain is preferentially involved in the binding of
receptor-derived phosphopeptides while the cSH2 domain has
preference for the phosphopeptide incorporating the critical
PLCg1 phosphorylation site (pY783) in the cSH2-SH3 linker (Fig-
ure S5). To analyze the structural and functional implications of
Y783 phosphorylation and the potential for intramolecular
binding to cSH2, we obtained the crystal structure of a construct
incorporating nSH2-cSH2Y771F,Y775F (545–790) following phos-
phorylation on Y783 (Figure 4A; Table 1). The structure of the
tandem protein revealed an intramolecular interaction between
the cSH2 canonical pY-peptide binding site and residues
781GFpYVEANPM790 (Figure 4A). Residues 774 to 780 are not
visible in the electron density map suggesting that this part of
the linker remains disordered. To orient the FGFR1 binding site
on the tandem domain, we have indicated surfaces on the
nSH2 corresponding to parts of the FGFR1 canonical and
secondary binding sites (Bae et al., 2009; Figure 4A). The struc-
ture shows that the cSH2 domainmakes an essentially canonical
binding interaction with the extended linker in which the pY783
side chain makes multiple interactions with three arginine
(R675, 694, and 696) side chains in the conserved pY-binding
pocket (Figure 4B). The side chains of residues pY+1 (V784)
and pY+3 (A786) are directed into shallower, hydrophobic
pockets (formed by cSH2 residues F706, L726, L746, and
Y747). The side chains of V784, A786, and P788 all make van
der Waals contacts with the cSH2 domain, burying 620 A˚2 of
solvent accessible surface. Intriguingly, some less definedStructure 20, 2062–20density is also observed in the peptide-binding groove for cys-
tals obtained for the nonphosphorylated tandem nSH2-cSH2
protein, suggesting that in the absence of other interactions
that might take place within the full-length PLCg1 (see further,
Figure 5) the region of the cSH2-SH3 linker has certain affinity
in cis for the pY peptide binding site even in the absence of
Y783 phosphorylation.
Although the structure of the cSH2 domain is not affected
upon pY783 binding, a further, more detailed comparison of
the crystal structure of the phosphorylated nSH2-cSH2 protein
with the nonphospho (apo) construct in the same crystal form
shows general similarity with some subtle differences in angle
and distance between the domains (not shown).
To test the functional implications of this structural integration
of the nSH2 and cSH2 domains and changes that accompany
binding of pY783 (and surrounding residues), we compared non-
phospho and phospho forms of the tandem nSH2-cSH2 for their
ability to interact with FGFR1. Isothermal titration calorimetry
(ITC) was used to determine the relative affinity of tandem
nSH2-cSH2 constructs for FGFR1-1p (pY766, binding site for
PLCg1; Table 2; Figure 4C). For wild-type nSH2-cSH2 protein,
biphasic binding isotherm was obtained that could be fitted to
a two-site binding model. The higher affinity component (attrib-
uted to nSH2 binding) exhibits exothermic behavior and a KD
of 5 ± 1 nM, while the lower affinity (binding to cSH2) shows
endothermic behavior and a KD of 81 ± 16 nM. Measurements
performed with nSH2-cSH2Y771F,Y775F tandem phosphorylated
to a high level at Y783 show a strikingly different binding
isotherm. In this case, a dominant equimolar interaction attrib-
uted to interaction of FGFR1-1p with the nSH2 domain is main-
tained. However, the second binding phase is highly suppressed
due to occupancy in cis of the canonical pY-binding site on the
cSH2 by the pY783-linker region. Interestingly, in this latter
instance the binding of FGFR1-1p to the nSH2 domain (KD
44 ± 11 nM) is nine-times weaker than in the case of the non-
phosphorylated tandem construct.
Similar measurements were conducted with the gSA and
FGFR1-1p (Table 2; Figure 4C). The finding that the binding
isotherm has only a single component suggests that within the
gSA only the nSH2 domain is available for interaction with
FGFR1-1p. Furthermore, attempts to use ITC to analyze binding
of phospho-gSA to FGFR1 suggest that similar to the case with
the tandem SH2 protein, Y783 phosphorylation reduces the
affinity (data not shown). To overcome a limitation resulting
from nonhomogeneous in vitro phosphorylation of gSA, we
used constructs incorporating a Y783F point mutation and
analyzed association with immobilized FGFR1-3p (pY766,
pY653, pY654) under conditions where proteins are either non-
phosphorylated or phosphorylated (Figure 4D). Using this
approach, we found that the otherwise robust association of
FGFR1-3p with gSA is reduced following phosphorylation of
the wild-type protein, whereas a similar reduction was not
observed for the Y783F variant.
Together, the data shown in Figure 4 suggest the possibility of
a previously unidentified consequence of the phosphorylation of
Y783 and its interaction with the cSH2 binding pocket, namely,
a weakening of the affinity between the gSA and FGFR1. In con-
trast, the link between Y783 phosphorylation and an increase in
PLC activity is strongly supported by several lines of75, December 5, 2012 ª2012 Elsevier Ltd All rights reserved 2067
AB
C
D
Structure
Interaction Domains in PLCg Regulation Mechanisms
2068 Structure 20, 2062–2075, December 5, 2012 ª2012 Elsevier Ltd All rights reserved
Structure
Interaction Domains in PLCg Regulation Mechanismsexperimental evidence reported previously (Suh et al., 2008) as
well as by our findings in the context of stimulation by FGFb (Fig-
ure 1). To provide a molecular mechanism to rationalise this link,
we extended our experiments to include a multidomain
construct of PLCg1 incorporating the PH, EF-hand, catalytic
and C2 domains (PLC-core).
Our previous analysis of PLCg variants (Everett et al., 2011)
and data from others (Gresset et al., 2010), demonstrates that
a deletion of the cSH2 domain and, under some conditions of
the spPH domain, results in an increase in PLC activity. Despite
this extensive analysis of PLC activity of various deletion vari-
ants, direct binding experiments between domains within the
gSA and the PLC-core have not been reported. NMR titration
experiments performed with 15N-labeled cSH2 domain, nSH2
domain or spPH domain and increasing concentrations of unla-
beled PLC-core protein, demonstrate that changes in the NMR
spectrum were only observed for the cSH2 domain (Figure 5A).
Furthermore, addition of a PLCg1-derived phosphopeptide
from the cSH2-SH3 linker (779NPGFpYVEANPMP790) completely
reversed the broadening of cross peaks in the spectrum. Impor-
tantly, analysis of the spectrum at different titration points iden-
tified chemical shift changes for residues positioned on a region
of the surface of the cSH2 domain that partly overlaps with the
phosphopeptide-binding groove (Figure 5B). Both NMR experi-
ments and ITC measurements are consistent with a KD value
of about 25 mM for the interaction of these proteins in trans,
and the observation from the ITC measurements of weak
endothermic behavior further suggests the involvement of elec-
trostatic contacts (Table 2). Based on this information we
selected a number of residues for mutagenesis and subse-
quently analyzed their impact on PLCg activity and affinity
between the cSH2 domain and the PLC-core.
Among a number of charge reversal mutations for the cSH2
domain, R748E and R753E have a marked effect on PLC activity
in cells, showing higher basal activity and enhanced activation,
and loss of a measurable interaction between the cSH2 domain
and the PLC-core in vitro (Figures 5C and S6A; Table 2). Two
other mutations, N728D and S729Y (the latter based on the
PLCg1 equivalent of a disease linked-mutation in PLCg2), have
a similar effect. Our previous studies of the PLC-core that iden-
tified a cluster of negative residues near the active site opening
and some specific residues in this region as important for low
basal PLC activity (Everett et al., 2009), suggest that this region
could be involved in an auto-inhibitory interaction with the cSH2Figure 4. Structure and Properties of the nSH2-cSH2 Tandem Incorpo
(A) Overview of the structure of the nSH2-cSH2Y771/775F, pY783 intramolecular c
representation of the structure show the nSH2 domain in blue and the cSH2 in gre
surface topology. Amino acid residues 774 to 780, not visible in the crystal structur
contacts with the FGFR1 kinase domain pY766 and secondary binding site are s
(B) Close up of the interaction interface is viewed from above with important amin
panel) represented as ball and sticks. In the left panel, the cSH2 surface is repres
representation showing the secondary structure elements. Dashed black lines re
(C) ITC curves for the interaction of FGFR1-1p kinase domain with PLCg1 nSH2-
panel). The bottom panels show the integrated heats as a function of the molar rat
of the titrant and subsequently, fit to either a two-site model (left and middle pan
(D) Pull-down analysis of gSAwt and gSAY783F proteins using immobilized FGFR
supernatant after incubation are also shown. The main panel shows proteins stain
shows the quantification of the PLCg1 proteins that were bound to the immobiliz
See also Figure S5.
Structure 20, 2062–20domain. Mutations in this region of the PLC catalytic domain
reveal that D1019K and, to a lesser degree, E347K replacements
affect the basal activity and level of activation of PLCg1 (Figures
5C and S6B). Remarkably, the D1019K PLC-core protein
completely loses its ability to interact with the cSH2 domain
(Table 2). Thus, mutagenesis experiments and NMR titration
data suggest that the cSH2 domain from the gSA solely interacts
with the PLC-core and forms the autoinhibitory interface that
involves residues at the active site opening. The titration exper-
iments with the phosphopeptide corresponding to the cSH2-
SH3 linker further imply that this interaction can be released
following Y783 phosphorylation and intramolecular association
with the cSH2 domain.
Mechanistic Implications
The findings described in Figures 4 and 5 are based on experi-
ments that focus on the gSA; they suggest that the main effects
of PLCg1 phosphorylation by FGFR1 are a weaker interaction
between the two proteins and the release of auto-inhibition in
PLCg1. To further establish that these findings are relevant to
holo-PLCg1, we analyzed the interaction of the intact enzyme
with FGFR1, the activity of PLCg1 following phosphorylation
and the potential for conformational rearrangement within the
full-length PLCg1 molecule (Figure 6).
Using FGFR1-3p and the full-length PLCg1 protein in the pull
down assay described in Figure 4D, we compared the wild-
type PLCg1 protein with variants lacking either a functional
nSH2 (R586L) domain, cSH2 (R694L, R696L) domain, or the
Y783 phosphorylation site (Y783F; Figure 6A). As demonstrated
for the tandem nSH2-cSH2 and gSA (Figures 4C and 4D), the
association of wild-type PLCg1 protein with FGFR1 is greatly
decreased following phosphorylation. Furthermore, we could
also demonstrate that only a functional nSH2 domain is required
for the initial binding to FGFR1 (Figure 6A). This finding is consis-
tent with the data showing a single binding site for FGFR1 within
the isolated gSA (Figure 4C). In contrast, the mutations in the
cSH2 domain or removal of the Y783 phosphorylation site do
not affect initial binding to FGFR1 but have the distinct, common
effect of preserving the PLCg1/FGFR1 complex under condi-
tions that allow protein phosphorylation (Figure 6A). These find-
ings are in full agreement with the intramolecular interaction
between pY783 and the cSH2 domain and subsequent func-
tional consequences affecting the nSH2-cSH2 unit (i.e., reduced
binding to FGFR1) proposed above.rating p-Y783 Linker
omplex. Surface topology (shown as translucent gray surfaces) and ribbon
en. Amino acid residues 781 to 789 are represented as sticks and a darker gray
e, are represented by a dashed loop. The region on the nSH2 surface that forms
hown in red and cyan, respectively.
o acid residues of both the cSH2-SH3 linker (left panel) and cSH2 domain (right
ented by an electrostatic charge distribution and in the right panel as a cartoon
present hydrogen bonding and salt bridges.
cSH2wt (left panel), nSH2-cSH2Y771F, Y775F, pY783 (middle panel) and SAwt (right
io of titrant to protein in the cell. The data were corrected for the heat of dilution
el) or a one-site model (right panel).
1-3P in the presence and absence of 10 mM ATP. Proteins remaining in the
ed by colloidal coomassie after separation on SDS-PAGE gels. The right panel
ed FGFR1-3p after the incubation.
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Table 2. ThermodynamicQuantities for the Interaction PLCg 1 SH2Domainswith FGFR1-1p and the Binding of PLC-Core to the PLCg1
cSH2 Domain
Protein
Cell Syringe n KD (mM) DH
 (cal mol1) DS (cal mol1 K1)
nSH2cSH2WT FGFR1-1p
First Binding Event 0.98 ± 0.01 0.005 ± 0.001 6,501 ± 183 16.1
Second Binding Event 1.08 ± 0.02 0.081 ± 0.016 7,116 ± 230 56.3
nSH2cSH2pY783 FGFR1-1p
First Binding Event 0.998 ± 0.009 0.044 ± 0.011 8,307 ± 25 5.8
Second Binding Event 0.084 ± 0.11 6.45 ± 0.93 37710 ± 5130 150
gSAWT FGFR1-1p 1.03 ± 0.19 0.185 ± 0.061 7,093 ± 167 7.02
PLC-CoreH335A cSH2WT 1.14 ± 0.04 23.9 ± 5.0 586.9 ± 37.1 23.1
PLC-CoreH335A cSH2N728D 1.17 ± 0.06 49.5 ± 12.3 1,432 ± 134 14.8
PLC-CoreH335A cSH2S729Y 1.00 ± 0.04 61.3 ± 8.2 1,449 ± 97 14.3
PLC-CoreH335A cSH2R748E – NB NB
PLC-CoreH335A cSH2R753E – NB NB
PLC-CoreH335A,D1019K cSH2WT – NB NB
NB, no heat of interaction detected; PLC-Core H335A, PLC inactive variant with high protein yield.
Structure
Interaction Domains in PLCg Regulation MechanismsOur data showing that the nSH2 domain is required for initial
binding to FGFR1 (Figures 4 and 6A) while an intramolecular
interaction between pY783 and the cSH2 domain effects phos-
pholipase activation (Figure 5) also suggest that phosphorylated
PLCg1 retains high enzyme activity without the requirement for
sustained binding to FGFR1; this scenario has not been reported
in previous work that instead simply linked PLCg1 phosphoryla-
tion to its activation (Suh et al., 2008). Following phosphorylation
of full-length PLCg1 by FGFR1, we were able to isolate a phos-
pho-enriched form of PLCg1. Subsequent measurements of
PLC activity in vitro clearly show that this phosphorylated
PLCg1 has higher PLC activity although not as high as for
PLC-core (Figure 6B).
Based on the data related to themechanism of overcoming in-
tramolecular inhibition (Figure 5), it might well be expected that
PLCg1 phosphorylation is accompanied by a conformational
change. Small angle X-ray scattering measurements of phos-
pho- and nonphospho- full-length PLCg1 support this possi-
bility: the scattering-derived P(r) distance distribution suggests
that phosphorylation results in a less compact overall shape (Fig-
ure 6C; Table S1). Unfortunately, due to the complexity of the
full-length PLCg1 it was not yet possible to unambiguously
model this change in terms of a three-dimensional (3D) model
of the intact enzyme.Figure 5. Interaction of g1SA with the PLC-Core
(A) The two-dimensional 1H-15NHSQC spectra of 15N-labeled spPH, nSH2 and cS
131215, D488–933, H335A). For the cSH2 protein a further titration was perfo
chiometry of the three components of 1:1:1.
(B) Residue-specific values of Di for
15N-labeled cSH2 domain in the presence of 0
peak has been completely ‘bleached’ from the spectrum as a result of complex
a surface representation of the cSH2 domain in orange and those above 0.1 in re
residues cluster to a surface. A further surface representation of the cSH2 doma
important for binding the pY783 and surrounding amino acids.
(C) The effect of point mutations on basal and stimulated PLCg1 activity were mea
indicated point mutations in cSH2 (left and middle panel) and PLC-core (right pa
See also Figure S6.
Structure 20, 2062–20Taken together, the data obtained using the full-length protein
support a global model illustrated in Figure 7A. According to this
model, the strong interaction between FGFR1 and PLCg1 could
be transient and a more loosely interacting or released, phos-
phorylated PLCg1, with high enzyme activity, could make direct
interaction with the membrane and gain access to resident PIP2
phospholipid substrates. This could allow FGFR to processively
phosphorylatemany PLCgmolecules. Importantly, our structural
insights reveal the molecular mechanism that could underpin
this global activation mechanism. Notably, in addition to our
finding that the tandem SH2 domains effectively form a coupled
structural unit and could interact functionally, we also describe
the molecular mechanism of the release of auto-inhibition. As
depicted in Figure 7B, the autoinhibition imposed on the PLC
catalytic domain by the cSH2 domain is released by direct
competition between the segment of the cSH2-SH3 linker
surrounding pY783 and the surface on the PLC-core binding
to overlapping surfaces on the cSH2 domain.
DISCUSSION
Previous insights into the regulation of PLCghave confirmed that,
as for other PLC families, PLCg is autoinhibited by intramolecular
constraints, the release of which lead to enzyme activationH2 domain alone and after a 1:1 stoichiometric titration with PLC-core (residues
rmed with the PLCg1-phosphopeptide (NPGFpYVEANPMP) leading to a stoi-
.4 mole equivalent of unlabeled PLC-core (at this stage of the titration no cross
formation). Residues with Di values between 0.05 and 0.1 were mapped onto
d. Two-views of the cSH2 domain illustrate that a number of these amino acid
in is shown in gray with a number of blue residues which represent the region
sured in COS7 cells transfected with pTriEx4-PLCg1wt and constructs with the
nel). SD is represented by error bars.
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Figure 6. Analysis of Full-Length PLCg1
(A) Pull-down analysis of full-length PLCg1wt proteins and the inactivating
mutants for nSH2 (R586L), cSH2 (R694L, R696L) or phosphorylation (Y783F)
using immobilized FGFR1-3P in the presence and absence of 10mMATP. The
main panel shows proteins stained by colloidal coomassie after separation on
SDS-PAGE gels. The top panel shows the quantification of the PLCg1 proteins
that were bound to the immobilized FGFR1-3p after the incubation.
(B) In vitro reconstitution activity assay of purified PLCg1-core (13–1215,
D488–933), PLCg1 full-length and phospho-PLCg1 (in vitro FGFR1 phos-
phorylated) was performed at indicated protein concentrations. SD is repre-
sented by error bars.
(C) Comparison of SAXS data obtained for the unphosphorylated (red) and
phosphorylated (blue) full-length PLCg1; to obtain proteins suitable for
SAXS, multi Y to F variant of PLCg1 was used.
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2072 Structure 20, 2062–2075, December 5, 2012 ª2012 Elsevier Ltd(Everett et al., 2011; Gresset et al., 2010). However, a limitation of
these studies is a lack of understanding of the 3D organization of
these complex proteins, in particular of the regulatory region,
which would allow a deeper and more comprehensive analysis
of the molecular mechanisms. Using a combination of NMR,
SAXS, X-ray crystallography, and biochemical techniques, we
have been able to define the architecture of this region and its
interaction with the PLC-core to generate an overall picture of
how PLCg enzymes are regulated.
We demonstrate that among four domains present in the gSA,
the cSH2 domain and its C-terminal linker provide a focus for
most interdomain interactions both within the gSA and between
the gSA and the PLC-core. Restraints are imposed on the cSH2
domain by an apparently inflexible linker to the nSH2 domain.
Indeed the two SH2 domains could be thought of as forming
a single supramodule as defined by the NMR-derived rotational
correlation time (Figure 2C). In contrast, our data suggest that
the spPH domain and SH3 domain make weaker and more
transient interactions with the cSH2 or the linker region, respec-
tively (Figures 2D and 2E). Importantly, only the cSH2 domain
appears to be involved in binding to the PLC-core and based
on interactions using isolated fragments in trans, intramolecular
interactions in cis are likely to be quite strong (Figure 5). This
central position of the cSH2 domain within PLCg enzymes is in
full agreement with the findings that the deletion of the cSH2
domain in PLCg1 and PLCg2 results in release of auto-
inhibition and constitutive PLC activity (Everett et al., 2011;
Gresset et al., 2010). The relative flexibility and weak interactions
that involve the spPH and SH3 domains may allow better
adaptability to different interaction partners or simultaneous
recognition of multiple binding sites involved in the regulation
of PLCg. Such arrangements could, for example in the case of
PLCg2, facilitate regulation by Rac that binds directly to the
spPH domain (Bunney et al., 2009). This in turn could impact
on the auto-inhibitory role of the cSH2 domain on PLC
activity in its own right or in synergy with other inputs. Similarly,
the relative independence of the SH3 domain would allow
interactions that, as suggested for cCbl, are not involved with
auto-inhibition and enzyme activation but instead could be
linked to downregulation of the protein (Tvorogov and Carpenter,
2002). In the context of the activation by FGFR1, and more
generally for the activation by tyrosine kinase receptors, the tight
structural and functional link between the nSH2 and cSH2
domains is critical (Figure 7).
Studies in murine models (Abe et al., 2011; Yu et al., 2005) and
recent genetic studies of patients and their families (Ombrello
et al., 2012) have demonstrated a link between dominantly
inherited complex immune disorders and gain-of-function muta-
tions in PLCg2. Based on our initial characterization of these
disease-linked variants, the PLCg2 mutations and correspond-
ing mutations in PLCg1 seem to compromise the auto-inhibitory
mechanism (Everett et al., 2009). Indeed, two distinct deletion
variants found in PLAID patients lack portions of the cSH2
domain and likely disrupt proper folding of this domain and
almost completely remove the auto-inhibitory surface. Consis-
tent with this, PLAID mutants of PLCg2 appears to be con-
stitutively active (Ombrello et al., 2012). Interestingly, a point
mutation in the cSH2 domain (S707Y in PLCg2), found in a
family characterized with another set of immune disorderAll rights reserved
Figure 7. Global and Molecular Models for
PLCg Activation and Signaling Deregulation
(A) The two-step global model illustrating activa-
tion of PLCg through recruitment and phosphor-
ylation by receptor tyrosine kinases and the
subsequent release and membrane binding.
(B) An illustrative summary of the molecular
mechanism of autoinhibition and phosphorylation
induced activation in PLCg. The gSA is shown as
a gray envelope with the cSH2 region in blue.
Amino acid residues in PLCg1 shown to be
important for autoinhibition are colored in yellow
and labeled. Similarly, the PLC-core is shown as
a gray envelope with the catalytic domain (con-
taining the active site) colored green. The under-
lying cartoon representation of this region is based
on homology to the PLCd1, PLCb2 and PLCb3
PLC-core structures. The surface of the PLC-core
above the active site is colored purple and is
suggested to interact with the cSH2 domain in the
inactive state. Phosphorylation of PLCg1 causes
the intramolecular binding to the cSH2 domain of
pY783 and surrounding amino acid residues (red).
This interrupts the interaction of the PLC-core with
the cSH2 domain leading to the active site gaining
access to the membrane and therefore enzyme
activation. Most mutations found in immune
disorders map to cSH2 domain (blue) and the
surface above the active site (purple).
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PLCg1. As shown (Table 2; Figure 5C), this mutation reduces
the interaction between the cSH2 domain and the PLC-core
and results in an increase in basal activity (albeit less
pronounced than for PLAID deletions) and a notable enhance-
ment of PLC activity following stimulation. This is similar to the
effects of other point mutations in PLCg2 found inmurinemodels
(Ali5 [D993G] and Ali14 [Y495C] loci corresponding to D1019
and Y509 in PLCg1, respectively; Everett et al., 2009). Ali5,
located in the PLC-core, corresponds to a residue mutated
here to a oppositely charged amino acid (D1019K). This mutation
has the most striking effect on both, increasing basal enzyme
activity and direct binding between the cSH2 and PLC-core
(Table 2; Figures 5C and S6B). Intriguingly, the Ali14 mutation
locus appears to be at the interface of the spPH and cSH2
domains, mapped here by NMR (Figure 2D); similar, activating
mutations were independently reported in PLCg1 (DeBell
et al., 2007). These results are therefore consistent with the
possibility that the spPH-cSH2 interaction could indirectly affect
auto-inhibition.
Although many signaling enzymes, including tyrosine phos-
phatases, tyrosine kinases, lipid kinases and phospholipases,
are constructed with structurally homologous modular domains,
it is clear that distinct mechanisms must have evolved to
control their activities. The diversity of these mechanisms is
also clear from comparison of different Src, Abl, Syk and Fes
family kinases. For example, several structures have shown
that SH2 domains of tyrosine kinases such as Src, Abl, and
Zap70 have an ability to suppress kinase activity through intra-
molecular interactions (Filippakopoulos et al., 2009). Recently,
the structure of the SH2 domain linked to the kinase domain of
Fes revealed that the SH2 domain can also stabilize the activeStructure 20, 2062–20kinase conformation, in this case by direct interactions with
the regulatory aC helix; this interaction is further stabilized by
ligand binding to the SH2 domain (Filippakopoulos et al.,
2008). In such cases, kinase activation could be closely coupled
to substrate recognition through cooperative SH2-kinase-
substrate interactions. In the lipid kinase PI3Kb two SH2
domains bind to the regulatory region, that encloses the catalytic
and activation loop, and impose autoinhibition (Zhang et al.,
2011). Nevertheless, despite the diversity, what seems to be
a main common theme for structurally defined proteins incorpo-
rating SH2 domains is that SH2 domains involve allosteric regu-
lation of the catalytic function. One notable exception is the
nSH2 domain of SHP-2 tyrosine phosphatase that binds to the
phosphatase domain and directly blocks its active site (Hof
et al., 1998). It is also usually the case that the same SH2 domain
that interacts with an catalytic domain also binds directly to a pY
motif within regulatory proteins; examples include SH2 domains
from Abl, Fes, SHP-2, and PI3Kb (Filippakopoulos et al., 2009;
Hof et al., 1998; Zhang et al., 2011). The mechanism for PLCg
has some quite different, distinct characteristics shown here
in the context of regulation via FGFR1. Notably, the function of
the binding to FGFR1 and the intramolecular interaction with
the PLC-core are distributed between two SH2 domains. The
nSH2 interacts with upstream receptors (showing no conforma-
tional change upon binding) and itsmain function is to recruit and
facilitate phosphorylation in trans (Figures 4 and 6). The cSH2, in
contrast, makes contacts with the PLC-core and recognizes an
intramolecular pY motif rather than a receptor site. It also seems
that a relatively small change in the tandem cSH2-nSH2—
induced upon pY783 binding to cSH2—is allosterically relayed
to the nSH2 domain reducing the affinity for FGFR1 but with
no corresponding allosteric effect on PLC activity. Instead, it is75, December 5, 2012 ª2012 Elsevier Ltd All rights reserved 2073
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Interaction Domains in PLCg Regulation Mechanismslikely that the cSH2 acts as a lid with precise contacts with
the PLC-core that becomes removed by interaction with the
pY783 motif (Figure 5). This mode of regulation (Figure 7) is
consistent with the observations that the PLC catalytic domain,
a TIM barrel, forms an effectively rigid structure, not influenced
by substrate binding (Bunney and Katan, 2011). This is also in
agreement with the regulatory models proposed for other PLC
families, which have in common that autoinhibition is mainly
brought about by active site occlusion, and in the case of
PLCb2/3 and PLCd1 enzymes, by more flexible and mobile
elements (Hicks et al., 2008).
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification of Recombinant Proteins
Genes or their fragments to be expressed were cloned into pOPINS (Oxford
Protein Production Facility), pTriEx4 or pTriEx6 (Novagen). E. coli strain
C41(DE3; Lucigen) or the mammalian cell line Freestyle 293F (Invitrogen)
were used following manufacturer’s instructions. Purification was performed
using Ni2+ chelating chromatography with cleavable His-tags. An expanded
set of procedures can be found in the Supplemental Information.
Crystallography, NMR, and SAXS Measurements
Proteins were prepared as outlined in the Supplemental Information and phos-
phorylated by FGFR1 where indicated. Crystals of both apo and phosphory-
lated nSH2-cSH2 were prepared by the hanging drop vapor diffusion method.
Conditions and further details can be found in the Supplemental Information.
Final images were created using the program PYMOL.
All NMR experiments were carried out at 25C on Varian INOVA or
Bruker AVANCE spectrometers operating at 14.1 T or 16.5 T equipped with
a cryoprobe. Details of data processing, semiquantitative analysis of cross-
peak broadening and molecular modeling are given in the Supplemental
Information.
Synchrotron SAXS data were collected on the EMBL X33 camera with a
Pilatus detector on the storage ring DORIS III (Deutsches Elektronen-
Synchrotron, Hamburg, Germany) and ESRF ID14-3 camera with a Pilatus
detector (ESRF, Grenoble, France). Details of data analysis with DAMMIN
andMONSA software packages are supplied in the Supplemental Information.
Functional Assays
ITC experiments were carried out with either a Microcal VP-ITC machine (as
described in Bunney et al., 2006, 2009) or an iTC200 system (MicroCal). Exper-
imental details are supplied in either figure legends or the Supplemental
Information.
Pull-down assays with immobilized FGFR1 and various constructs of PLCg1
were performed with Streptactin Macropore beads following manufacturer’s
instructions. Specific experimental conditions can be found in the Supple-
mental Information.
Assays of PLC activity in COS7 and PAE cells were carried out as
outlined in (Bunney et al., 2009; Everett et al., 2009) with experimental differ-
ences outlined in the Supplemental Information. Details of PLC activity
measured in vitro, described in (Bunney et al., 2009), and other assays asso-
ciated with measuring protein function can be found in the Supplemental
Information.
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